ABSTRACT Aim: Coeliac disease is a common but markedly under-diagnosed condition, which may lead to serious long-term complications if untreated. Both the diagnostic yield and true incidence have significantly increased during the last few decades and it is now one of the most common chronic gastrointestinal conditions in children. The aim of this review was to summarise the current concepts on screening for coeliac disease in children and adolescents.
INTRODUCTION
Coeliac disease is an immune-mediated disease in which dietary gluten drives small-intestinal damage and subsequent clinical manifestations in genetically predisposed individuals (1) . Both the diagnostic yield and true incidence of the disease have significantly increased during the last few decades and coeliac disease is now one of the most common chronic gastrointestinal conditions in children (2) (3) (4) . Unfortunately, coeliac disease is not very easy to recognise and the great majority of patients remain unidentified or have a markedly delayed diagnosis (2, 5) . This may have significant individual and public health consequences, since untreated coeliac disease is associated with many potentially serious long-term complications (6, 7) . The diagnostic yield could be improved by screening at-risk subjects or even the whole population using modern serological tests, but the practical implementation and benefits of this approach remain controversial (8, 9) . There is a scarcity of evidence about coeliac disease, especially the cost-effectiveness of screening and long-term benefits of the demanding treatment with a gluten-free diet in asymptomatic screen-detected patients (8, 9) . This review summarises the current position on screening for coeliac disease in children, based on the World Health Organization's screening criteria (10) . We focused on papers published in English from the start of this century.
A COMMON BUT UNRECOGNISED CONDITION
The number of patients diagnosed with coeliac disease has increased significantly during the past few decades (3, 4) . The main explanations for this sharp rise are likely to be better recognition of the condition by physicians, more active case finding and the availability of practical methods for non-invasive testing of suspected patients (3) . Interestingly, there is also evidence that the actual incidence of coeliac disease is increasing (3, 4) . In the last few decades, screening studies based on population samples have estimated the true prevalence of coeliac disease to be as high as 0.4-3.0% depending on the age and geographical area of screening. In contrast, the present-day prevalence in clinical practice remains several-fold lower (Table 1 ). This considerable mismatch between the diagnosed and unrecognised cases reported in virtually all recent studies underlines the challenge of clinically recognise coeliac disease and has usually been considered as the primary reason to advocate wide-scale screening (9) .
WHY THE DIAGNOSIS IS SO DIFFICULT: VARIABLE CLINICAL PRESENTATION
Identifying coeliac disease in daily practice is challenging, mainly because of the particularly heterogeneous and fluctuating clinical presentation (11) . This is despite the fact that in numerous studies patients have reported that they suffered from disturbing symptoms even 10 years or more before they were diagnosed (5, 12) . Classical malabsorptive symptoms and diarrhoea are probably the bestknown signs of the disease amongst general paediatricians and general or family practitioners, who are usually in the first line when it comes to recognising possible celiac disease patients. In contrast, more atypical features, such as mild abdominal pain, nausea and constipation, and variable extra-intestinal complaints, including dermatitis herpetiformis, arthralgia, neurological symptoms, and isolated anaemia, are far less known. An additional challenge with many of these manifestations is that they occur frequently in other medical conditions and consequently have an unspecific nature (13) . Under-diagnosis of coeliac disease does not just depend on physicians. Often patients themselves do not contact healthcare professionals if they experience vague symptoms that they consider are part of normal life. Sometimes they only realise they have a problem with gluten when their coeliac disease is eventually recognised and treated (14, 15) .
DIFFERENT APPROACHES TO IDENTIFY COELIAC DISEASE
The three main approaches to recognising individuals with untreated coeliac disease are case finding, screening for known at-risk groups and mass screening at the population level. However, this is a simplified classification, and, in particular, distinguishing between active case finding and risk-group screening can be somewhat vague. In any case, the remarkable differences in diagnostic yield between each approach can be easily seen (Fig. 1) .
Active case finding
The effectiveness of case finding is obviously dependent on the awareness of the different manifestations of the disease. Until the early 1980s, coeliac disease was considered to be a rare condition that affected less than 0.1% of the population and had a characteristic presentation of malabsorption and failure to thrive in infancy. Thereafter, improved diagnostic methods and recognition of the variable clinical spectrum and age at presentation led to a rapid increase in the incidence (3, 11, 16) . Active case finding can be defined as having a low threshold for suspecting the disease when there are indicative symptoms or findings. In children, special attention should be paid to evaluating possibly abnormal growth and/or puberty status. At all ages, vague unexplained complaints and abnormal laboratory findings associated with coeliac disease should lead to further investigations (17) . However, even when this approach is at its best, only those who seek medical help or attend routine medical examinations can be found (Fig. 1) . This raises equity concerns, as such an approach may favour those with better socio-economic status or otherwise earlier access to healthcare. Then again, screening may also find patients without access to further treatment or follow up, which is another ethical problem.
At-risk group screening
We have known for quite a long time that the risk of developing coeliac disease is markedly increased if there is a family history of the disease or if the patient has certain coexisting autoimmune diseases (Fig. 1) . Approximately, 5-11% of the first-degree relatives of the patients are affected, even if they are not always diagnosed, although this percentage varies depending on the precise relationship with the index case (18) . In identical twins, the concordance of the disease can be as high as 80% (18) . Other particularly well-defined at-risk groups for coeliac disease are subjects with type 1 diabetes, autoimmune thyroidal disease, selective immunoglobulin A deficiency and Down syndrome (Fig. 1 ). The prevalence of coeliac disease in these individuals is also approximately 5-10% (17) . There are also many other immune-mediated disorders, such as Sj€ ogren's syndrome, psoriasis, vitiligo and inflammatory bowel diseases, which have been reported to exhibit an increased prevalence of coeliac disease. However, the actual risk ratios are lower or less well defined in these disorders than in the previously mentioned conditions and it is difficult to judge whether they confer sufficient overrepresentation for routine screening. In fact, evidence of the benefits is scarce and the recommendations for screening are controversial in all coeliac disease risk groups (Table 2) . In any case, children with a family history of coeliac disease and those with type 1 diabetes are regularly screened in many centres. For example, we reported that approximately 30% of all new paediatric coeliac disease patients were found by screening in Finland (19) . Based on the experience from Scandinavian countries, it could be estimated that approximately one-third to a half of all patients could be found by combining active case finding and low threshold screening for at-risk groups (11, 20) (Fig. 1) .
Mass screening
The only approach that would enable the detection of almost all coeliac disease patients, at least at a certain age, would be wide-scale screening for the whole population ( Fig. 1) . The number of people needed to be screened repetitively could in theory be reduced by genetic testing, as almost all coeliac disease patients carry the human leucocyte antigen haplotypes DQ2/8 and the condition is very unlikely if this is not present (17) . Thus, it would be possible to first define these haplotypes and then focus the screening for the remaining 20-30% genetically susceptible individuals. Nevertheless, this approach has been questioned since the human leucocyte antigen risk alleles are very common, for example, amongst those with type 1 diabetes and the relatives of coeliac disease patients. These individuals would be identified also by targeted risk-group screening (21) . Further unanswered questions are the right age for the first screening to optimise diagnostic yield and prevent permanent complications and how seronegative cases should be followed up. Interestingly, evidence provided by The Environmental Determinants of Diabetes in the Young, a prospective multicentre birth cohort study published in 2017, indicated that the great majority of genetically at-risk children developed coeliac disease autoantibodies before 10 years of age (22) . However, this may not be generalisable to all populations and it must be realised that new cases of celiac disease can appear at any age. Another concern is that serology might be less accurate in a general population with low pre-test probability than in evaluations focused on symptomatic or at-risk patients. (23) These limitations of the current serological tests must be taken into account when planning wide-scale screenings programmes.
SPECIAL DIAGNOSTIC CHARACTERISTICS IN SCREEN-DETECTED PATIENTS
Coeliac disease evaluations are usually initiated by measuring the disease-specific serum immunoglobulin A class tissue transglutaminase and endomysial antibodies. This is often carried out at the same time as the assessment of total immunoglobulin A level, to exclude immunoglobulin A deficiency (17) . Traditionally, the diagnosis must be confirmed by demonstrating the characteristic findings of mucosal inflammation and villous atrophy in duodenal biopsy. However, in 2012, the European Paediatric Society for Gastroenterology, Hepatology and Nutrition launched new criteria that stated that non-invasive diagnoses could be made in genetically at-risk symptomatic children with tissue transglutaminase antibodies that were more than 10 times the upper limit of normal and positive endomysial antibodies (17) . Biopsies are still required in all asymptomatic children and those with lower antibody levels. Although these strict limitations increase the diagnostic accuracy, they pose particular problems for screen-detected children who are often apparently asymptomatic and may present with low or fluctuating tissue transglutaminase antibody levels (24) . In addition, even if they undergo biopsies, some screened patients have normal duodenal histology or just an early developing mucosal lesion with normal villi (25) . Thus, these individuals do not fulfil the new non-invasive criteria or the classical histological criteria for coeliac disease and may have to undergo repeated serological and endoscopic investigations before they are eventually diagnosed. There is evidence that many seropositive patients can already have symptoms and signs of coeliac disease and benefit from a gluten-free diet or develop villous atrophy if they continue to consume gluten (25) . On the other hand, a significant number may remain in full clinical and histological remission for an extended period of time (26) . We can assume that wide-scale, early screening for children would substantially increase the number of detected cases and there needs to be an evidence-based consensus on how to deal with such patients before any screening is launched.
CONSEQUENCES OF A MISSED OR DELAYED COELIAC DISEASE DIAGNOSIS
An important reason for coeliac disease screening is the possibility of preventing the long-term complications associated with untreated disease (Fig. 2) . Also, apparently asymptomatic patients may already have advanced histological damage and thus increased risks for complications such as osteopenia, underachievement and impaired growth (27) (28) (29) (Table 3) . On the other hand, the evidence about the risks for severe long-term complications, such as infertility, osteoporotic fractures, malignancies and increased mortality, in unrecognised coeliac disease patients is controversial (8, 9) . Another important, but currently open, question is whether the risk for other autoimmune diseases could be reduced by an early diagnosis and initiation of a gluten-free diet.
It is important to realise that being detected by screening does not mean that someone is asymptomatic. In fact, studies have shown that a substantial proportion, even the majority, of screen-detected coeliac disease patients suffer from unrecognised clinical symptoms at diagnosis (Table 3) . Furthermore, as already mentioned, many patients originally classified as asymptomatic find a gluten-free diet beneficial. Besides the unnecessary burden of ongoing symptoms, delayed diagnosis seems to increase the risk for more severe or non-responsive coeliac disease, which would again support screening (30) .
EFFECTS AND ACCEPTANCE OF A GLUTEN-FREE DIET
The only official treatment for coeliac disease is a life-long gluten-free diet. In practice, this means completely avoiding dietary wheat, barley, and rye and a wide variety of products with added gluten (1). In theory, a strict diet initiated in early childhood could prevent all, or almost all, of the permanent complications of coeliac disease (Fig. 2) . However, even if it is effective, the implementation of the gluten-free diet can be very challenging and socially restrictive and can negatively affect the patients' quality of life, particularly if the actual clinical benefits are considered minor, as they could be in screen-detected patients (15) .
Initiation of dietary gluten
Mucosal inflammation, increased permeability, malabsorption, vitamin deficiencies, etc. Figure 2 Mechanisms and development of variable long-term complications associated with untreated coeliac disease. Risk of complications varies according to the age of a patient at the beginning of the disease. In order to prevent most of the permanent complications, the estimated optimal age for screening would be in early infancy. However, it must be realised that coeliac disease may develop at any age. Availability and expense of a gluten-free diet Gluten-free products can be significantly more expensive and challenging to find than products containing gluten. Furthermore, their availability seems to be the poorest in budget supermarkets and corner shops, which means that patients with lower socioeconomic status have more difficulties with their everyday shopping (31) . The same problems exist when people eat out as the knowledge of coeliac disease varies substantially in restaurants and cafes and this affects the availability and quality of gluten-free options. Fortunately, the gluten-free diet has also become more popular amongst people in the general population in recent years, making products cheaper and easier to find than before (32) . Having said that, there is often confusion between people who choose to follow the trend to avoid gluten and those who do so because they have coeliac disease and need to follow a strict diet.
Dietary adherence
In general, adherence to a gluten-free diet by paediatric coeliac disease patients has been reported to vary between 23% and 100% (Table 4) . It has been assumed that screendetected patients have more difficulties accepting the diet, because they often suffer from milder symptoms and could find strict gluten avoidance particularly challenging.
However, whether the diagnostic approach of coeliac disease truly affects the motivation or strictness of the treatment is controversial and many studies have shown that even asymptomatic patients have excellent dietary adherence (Table 4 ). In fact, adherence might depend more on how easy the treatment is, which can be affected by a number of factors. These include the price and availability of gluten-free products, the education and follow-up of the affected individuals and patient-dependent characteristics, such as their education level and age at diagnosis (33) (34) (35) (36) (37) . Therefore, a good availability of reasonably priced glutenfree products and supportive healthcare systems could be considered as a prerequisite for wider scale screening for coeliac disease.
Quality of life
A very important issue when considering the implementation of coeliac disease screening is the effect that diagnosis and treatment have on an individual's self-perceived quality of life. Untreated coeliac disease predisposes people to impaired quality of life due to different somatic and psychological symptoms (15, 38) . Accordingly, quality of life has been show to improve after the initiation of a gluten-free diet in symptomatic patients (38, 39) , but this is less evident in screen-detected patients who may already be comparable to the healthy population at diagnosis (14, 15, 40) (Table 4 ). There are concerns that the laboriousness and restrictive nature of the dietary treatment may actually lead to decreased quality of life in screen-detected and asymptomatic individuals (15) . However, it must be realised that an individual's quality of life and experience of the treatment can also be markedly affected if they find their gluten-free diet easy and successful (41) . A limited number of studies about quality of life have been conducted on screen-detected children and adolescents on a gluten-free diet, but so far, the results of these have been similar, or even better than, in patients detected as a result of clinical investigations or in population controls, at least in countries with a good availability of gluten-free products ( Table 4 ). The significance of clinical presentation at diagnosis and the diagnostic approach may be less important in children, because their parents usually take care of the selection and purchase of gluten-free products. As a result, patients diagnosed in early childhood might accept their diet as a normal part of their life and demonstrate better quality of life and dietary adherence than those diagnosed later (42, 43) . However, early diagnosis could also be a risk for poor treatment motivation later in adulthood if the reason for the coeliac disease diagnosis remains unclear.
ECONOMICAL ASPECTS OF SCREENING
Studies that have evaluated the cost-effectiveness of coeliac disease screening are rare and unavoidably based on many assumptions. Estimating the overall expenses of untreated and treated coeliac disease and the effects of screening in these patients is difficult. This is because the costs are affected by several different, and even opposing, factors, such as the price of the diagnostic tests, the prevalence of coeliac disease in the population, the availability of gluten-free products and possible reimbursement for extra food costs by the government (44) . In any case, both unrecognised, symptomatic patients and also diagnosed patients can generate healthcare costs, although for different reasons. Long-term unexplained symptoms may cause an incremental use of healthcare services and medication, which decrease after coeliac disease is diagnosed (12) . Then again, patients who are recognised by screening obviously need initial diagnostic evaluations and then regular follow-up visits, which also cause economic burdens for healthcare. However, the possible severe complications caused by a markedly delayed or missed coeliac disease diagnosis could also be very expensive. Overall, the data on this are limited and there is currently insufficient evidence to estimate the economic aspects of coeliac disease screening.
CONCLUSION
There is good evidence that the diagnostic yield in coeliac disease could be significantly increased by screening. However, whether this approach should be applied more actively, and at what age, remains poorly defined. When this is compared to the general criteria for screening (10) , the most significantly unclear issues are the long-term benefits of screening for asymptomatic patients, the diagnosis and treatment of those with early developing or potential coeliac disease and economic issues. There is moderate evidence to favour screening the first-degree relatives of coeliac disease patients and maybe those with type 1 diabetes, whereas the benefits of screening for other at-risk groups, let alone the general population as a whole, are unclear. However, most celiac disease patients will remain unrecognised if we wait for the results of future studies, without screening. The possible risk these patients face, for even permanent complications, should be balanced against our current knowledge about the benefits of screening until more evidence becomes available.
